03:45 PM EST - Zomedica Pharmaceuticals Corp. : Opened its third Investigational New Animal Drug (INAD) application with the U.S. Food and Drug Administration Center for Veterinary Medicine (FDA-CVM) for ZM-007. ZM-007 and the previously announced ZM-012 are complementary oral formulations being developed for the treatment of diarrhea in dogs. Zomedica Pharmaceuticals Corp.
shares V.ZOM are trading unchanged at $1.28.
